Iron Hill Capital establishes and provides promising companies and management teams with meaningful capital resources and assists them in achieving their growth objectives.  Our goal is to help build sustainable companies capable of achieving a strong position in the marketplace. 

We have a differentiated strategy that focuses on small and mid size businesses typically from $50-500 million in enterprise value, and a deep understanding and appreciation of the unique challenges and opportunities such businesses present.

Iron Hill Capital seeks to invest in the best opportunities in emerging life sciences companies. We like to back businesses with rapid growth potential and look for the next market leaders regardless of the company stage. We focus on companies that have seasoned management with a strategic vision and we believe management excellence makes the difference between success and failure for any business.  Our experience tells us that in life sciences only companies committed to quality will succeed beyond the short term. It is this combination that we look for in any investment we make.

We may invest anywhere in the world but have a particular focus on the U.S. and Asia.  We invest across all stages from venture to emerging company buyouts.  While we are able to invest in any sector of Life Sciences, our emphasis is on biotechnology and acquisition of mature pharmaceutical products with brand equity.